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Grade: · 95 
Excellent paperl Neat, clear, and carefully done. You show that you understand 
the subject. 
Suggest that you be more critical of reports on clinical trials of drugs . Certainly 
one must bear in mind the natural history of the disease under therapy. I would 
suggest that you investigate the natural history of acute leukemia. Do r emissions 
occur spontaneously, and how frequently? Why does anti FA Rx. affect the disease 
in children and not in adults? Does chemotherapy ever shorten the life expect ancy 
of these children? Remember that fatality is an unpleasant side-effect of these 
compounds. 
Finally, remeber that this approach to leukemia therapy does not attack any 
specific biochemical function of leukemia cells, but in j ures all cells, thus 
utilizing only a quantitative difference in behaviour, rather than any specific 
qualitative difference. 
E.J.F. 
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INTRODUCTION 
Ever since Paul Ehrlich, the father of modern cherno-
therapy, gave to the world its first concept of scientific 
chemotherapeutics with his organic arsenicals in the early 
1900's (1), scientists and investigators have strived for 
decades to apply the principles of chemotherapy to practical-
ly every infectious and communicable disease known to man . 
~enewed interest and a whole new impetus was given 
to the che~otherapeutic field by the discovery in 1935 of 
the bacteriostatic effects f the sulfonamides, and subse-
quent concept by Paul Fildes (2) of enzymatic co~petitive 
inhibition as a mode -of action of the sulfa compounds. 
It was almost to be expected, then, that with this 
inception of successful chemotherapeutic agents, eventually, 
they 1ould be used not only in the treatment of the myriad 
bacterial,viral, fungal, and rickettsial diseases which be-
set m~n, but also, as an ajded weapon against man 's most in-
"\. 
\ 
sidious and inherent parasite, the neoplastic cell. 
Sydney Farber (3) of Children's Hospital, 3oston, 
first sug~-ested " an acceleration phenomenon " in the leu-
kemic process in the marrow and viscera of children with acute 
leukemia who v:ere treated vli th the Folic Acid Conjugates, 
Pteroyltriglutamic and Pteroyldiglutamic Acid (4). He as-
sumed that if Folic Acid and its conjugates accelerated the 
leukemic process, the very recently discovered Folic Acid 
Inhibitors (3,5,6) might retard it. 
( 1) 
THE FCLIC ACID I NH I BI I'CrtS 
'rhe follo·,dng list of Folic .Acid (FA) antagonists 
(figures 2 ,3, 4, 5 , and. 6) as preserted by Dr. James Will iams 
(7), dire c to r of research at Lederle Laboratories, at theSe-
cond Conference on the Folic Acid Antagonists in th e Treatment 
of Leukemia, represents those antifolics wh i ch have been used , 
II either clinically or experimentally , or which are being used 
as such at the present time . 
According to Dr. Willia~s, activity of the s yn t hetic 
antagonists is narkedly enhanced ':Jy reulacemen t of t he hydroxyl 
' group in position 4 by an a~ino grnun . I nter estingly enough , 
II 
t his activity may be further increased by attachlng a methyl 
gr0up at position 10, whereas a methyl gr~up at nosi ti on 9 re-
duc gs the activity of the ant <ogonist to a greet extent . In 
additi on , r eulac ement of the £ 1 uta~i c acid residue by o ther 
I a:nino acids, e . g . As partic acids (5), likelo'rise appeared to 
ma r kedl y redu c e activity of the synthetic compounds. 
II At prese~ t , the long ist of antifnlics are g r adually 
giving way to al ~o st exclusive clinical use of AminoD terin, 
t he most nowerf ul yet synthesized (8). 
( 2 ) 
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THEORETICAL EOHANI SriS OF ACl'IO I OF ;:'HE FOLIC ACID PJ l'AGO~ ISl'S 
r e '' cce1 era .... or n er e11on" the e ~e~ic nr cess 
eocri~ed by F~rber (3 ue ~o ~A r s corrobor~te further 
by e perimen~a ror~ re by S~i uer et al (9). 
-his invest -
etor st ied ~~e effects of 1~r~e doses o FA a one, and 
in cor:.bina tieD ri th knino-oterir, on t .e ife span of nice 
vri th AK4 str in leuKerria, in ··;1-'ich an excess of FA ap eared 
to sueed UD the rno se leu {e. •ic orocess . 
Wor~ resente by Sa bPrlich { 0, 1) in 949, and 
"ich 1 IJ.t''d I•Te ch ( 12), anneared to s ges t t e FA vras con -
verted to Ci ~r vcrun Fe.ctor ( CF), 2 :-rc,·.rtr :'actor re,.,uired 
by L<=>l c Dnstoc ci trov ruT'l, by a red ct ve nnd f r"1Y :Jtior: 
st~ ( 10) . 
•A + For:nate (HC 
H2 
= 0 )~ CF Co - rzyne 
_____ L .., 
I ' 
: :C=O : 
'- ----- - -· 
For:n2tP tr r fer t .... he _ ~ber 2 rd 9 carbon is ab-
s~1ute1y e sentia1 in the synthesis of uriDes, the basic 
stn c ture of ecnroteins ( 12). 
Possib e nrecJrs rs 
F 
Pur ne slrr:>leton(l4) 
The incornor tion of cl4_f rma te in t'1.e ;;£-carbon 2 tom 
o ser ne ·m. u t be much hi~her (10 times in iver pro -
tein and 3 t mes as ~ ch in v sce~a roteir o~ rats) ir. ~o ic 
£i• tre ted rats ~s c~·~ared t F ic Aci dc~ici0nt rets 
by p ::JUt et el ( s). 
Sp:rinsor ( 16 ), 1·rho stu ie Eippuric acid excretion in 
nor~na and FA eficient rats of lrl5 - L Serine nd G ycine, ~ ro -
nosed the folloHing schema: ~Serine~ 
~ rmate Glycine 
~ 
and the concept that bot1 Serine and Formate could co b ne 
vri th F. , t us al ovring a11 interconversion bet1··een erine and 
Formate by a 11 ss or cain of a G JCine 710 ecul e'' . 
A11r ther "'eta o ic ro te :'or the or::-::ta te rroiety in 
n cleoprotein synt1csis, 'thnugh n t ;>roven) could be the 
a di ti n of for"'la te to ' - au no- 5- carboxar::idcimida.zo e nu-
cleoti e, thence to nter1e iates,an finalJy DFA and RNA (-
Guany ic an A eny ic acids~ concept base on the w rk of 
\Too ey and Print;le ( 17 1 who fo n an increase in 4 - amino - 5 -
carboxamidoidazole durine:; the crovrth of E. coli in t 1e pre-
sence of A~ino terin. 
Ha~2arsten et al ( 8) in their experi~er-ts added a 
:possible thir route to t e for:na. te pa thvray y the pr ba e 
a di tion of formate to Cytidir>e~Inter"r'e iate-----7 ~:A ( T y-
""li ylic aci ) an fina ' a fourt _ ro te '\·rae theorized by 
~re chan Sal:ani ( 9 in t _at abile foroai·e and internediates 
(not proven to "oe eue'1dent o , C ) ---4 CllOli'i..e -' ~ · etl}ion ne. 
The FA metabolic pathv.·ays can be illustrated by tJ.e 
ollo rins ia ram as presented by Dr . :~oi·rard Skipper at the 
Second Conference on ?o ic Acid ~ntaconists at Chil ren ' s 
:rospi ta in 1:arch of .751 ( 20 : 
(7) 
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The \·rei : ht of evidence seems to show , n ""' , that the 
more active f ormy ated conversl0n product of FA, the OF , re -
presents the essential ink in vita f ormate transfer for 
purine and nucleoprotein synthesis . Since nucleoprotein , es -
pecia ly Desoxyribosenuc eic Acid , is an essential co~~onent 
nf genes and chromosomes (21 and 22) in divi ing cells, it 
1
norhays should not have been so surprising that FA gave rise to 
t'1e '' accele:;:'a tor phenomenon" in the leukemic process ( 3 ). 
'-n in hi bi tion of F by its an ta.e;'"'nis ts of a compet-
. itive nature was describe by Hutchincs et al (5) 1r1ho SJnthe-
sized Pteroylaspc.rtic Acid and found it an ef:ective inh:ibi -
tor; which behaved in a comnetitive ::w.nrer '·rith uti1ization of 
Fteroylglutamic Acid ( PG~;) for ~ro;rth by Lac tobacilJus easel , 
Strentococcus feca . is R, an the chick ; hovrever, this group 
as uDable to obtain FG iDhibition with Pteroylaspartic Acid 
in the rat a~d Escherichia coli . 
ichol end ielch (23 ), though , in their experiments 
on rat liver slices/ with and without A:ninopterin1 found that 
in contrast to the reversible antagonism of a true competitive 
inhibition of "metabolite an t eir structural ana ogs , " · A1lin-
opteri n proved to be reverse very inef~icient y by PGA. It 
i·Jas assumed that A111inopterin , theref re, id not preferentially 
I antae;onize the PG OF step a::.one , but a so in some way conpeted 
vnth the OF derive from PGA. 
,,., 
it 
S .ipper, --i ~ c'bPl , "'nd Bennett (llL), iYJ their exneri -
the entasrYJists ~refound y decreased Lhe rate o~ S / nthesis of 
:,~uc l eic Acids, but did not inhi".:it cer"':::lon dioxide fixation in -
to the co!"tro .... issue. This led then -':.o :JostuJ ate a hichly 
differential blockinp: oy Aminon:.erin o:' ~r cleic Acid synthesis;, 
and thus, ef:'ecti vely and r1preferent1 lly inhi ~it leu::.•e'"lic cell 
::livisio'l , since neoulasrns a'Jp rel'1tly syDthesize ::'"ucleic Acids 'I 
·nore reDidly than ~ost tissue. u I'his preferential site of 'I 
ac tiol'1 on 11~uclei c Acid metabolis JJ las aFain sho\m by l e + er 
studies of Sk i uper , ~ell, and Cha:Jman in 1051 (24). These 
I \·ror>::0rs also snowed that DesoxyribosenuclPic e.cid consistentl y 1 
partial y reversed Ac iroD0erin , and Ri bosenucleic ocid shov:ed 
reve,sibi +.y, but not s rerularly . 
SchoenbPCt' et al (25 ) describe a temuoral relation -
s~i~ betwee~ a Ministration of FA and its antazcrist, Aminop-
terin. It ~ec a~e aDparent frcm their studies that FA ~ffpred 
DC Dro tee t ion · ha tsoever to Arnl.non+ erir- toY city ~·.'h en ad '"'"!in -
is tered sirnul taneously or subsequently to the an ta~:onis ts. 
<. or FA. •''"' s [i ver one h"ur bef ore A..,inonteri n, co ~ "') r:; te nro -
tectio!l vras obtained. Even ir'her rrassi ve a mounts of FA ( 50 - 75 
mg/ -e of ani ""Tlal) p us 10 "'[. o f krinooterin v1ere c:i ven simul -
t:u:eously, it f il"ld to in+~er""'ere v'ith the toxicity of the ant · ! 
folic. Such tre:nend0us doses v·ere fa"~" a bove the r"n r e 
for the drue: to act in a si JDl8 co ·,ryetitive manner . 
"10 ) 
II 
The ex~lanation offered by these workers was that the 
time interval (one hour) reauired between F a ,ninis tra tion 
and Aminopterin for com~lete protection might represent the 
period in -,rhich the mouse tissue rr converted or incoroora ted the 
FA into the protect ive netabo _ic product.'' I f Ami nopterin 
prevente1 this conversion, simultaneous administration of the 
tvm vou ld; therefore/ not allovl FA to form this nrotective pro-
duct . 
Greenspan et al (26) f llowed up these experiments 
with observati~ns that OF, even when given one hour subse1uent 
to suoralethal doses of A~ inopterin , gave protection to experi-
mental mice against repeated suoralethal doses of Amin opterin . 
These workers inferred that : 
111. Folic Acid is rapidly metabo ized within one hrur, 
into a more active state capable of successful comoetition 
with the antifo ic comprund. 
2. No neriod of activation is necessary for successful 
competition of CF with Aminopterin. 
3. Aminooterin interferes 1'11 th the enzyme.tic ccnversion 
of FA into the more active ~ etabo ic state . 
4. This inte r ference pers is ts after a sing e supralethal 
dose for at least three days . 
5. Animals ryro t ected from Amin pterin by either OF or 
FA nas ess an inapparent defect in an enzyme necessary f or 
c nversion of FA to a more active metabo ic state. 
( 1 
'-
--
6. Thi s deficiency may be manifested by failure of FA to 
protect from a subsequer:t dose of Aminopt::rin , desp i te main -
tenance of optimum time r e l a tion s hips . 
7. Conside rable excretion or conversion to inactive 
me tabolic products derived from either FA or OF probably 
occurs within 24 hnurs , since both FA and OF lose the greater 
part of their protective potency if their ad11inistra tirm is 
24 hours before t.:ninopterin . 11 
The work of Greenspa~ et al ( 26 ) thus lends sup~~ rt 
to the hy~othesis of Nichol a"nd Welch ( 23 ) that FA is convert -
ed. to OF presumably by a.n enzyme vlhich was design a t ed ''A". 
These workers hypothesized from their exp eriments ~hat lethal 
doses of Amino"Jterin 11 iiversi 'bly bound" sufficien t E1.1 zyme A, 
hence, synthesis of OF is tqrminat?d ; a~~ the nn e hour inter-
val betvieen FA and Am.:..nr-pt-·rin ad ninistration necessary for 
urotection c'Juld represent t he time required for t~~e .nax i r:mr.1 
conversion of FA to OF by Enzyme "A11 (25) . 
Greens~an ( 25 ) gave further evidence for acti0n on 
enzyme '' A" by observations ".:.hat l ethal toxicity protection was 
unobtainable after r 9uea ted ad~inistration of FA and Aoinop-
terin every 24 or 43 hours 11 even 1·hen the optimal ra tics and 
time relationships for single dose protection were employed . rr ' 
Also , FA T,res not effective up to 72 hours afte r t he last dose 
of OF and Aminouterin . It vras theorized , then , that even 
t~ough the tissue was ~rotected to the fullest fron a suura-
lethal dose of Amin0uterin by FA or OF , a definite change 
ar:mear s i n En zyme rr A" . 
(12) 
bined adniDistr~t.ion of "Jeta.boli te and ant.:q;crlist vnuld 5ive 
pro tee tion . ':lith repe:" ted su0lethe.l doses of AmiY'opterin, 
•:lith or vJi":.hout FA, the FI'<:,dual prosressive destruction of 
Enzyme n A 11 ',-ill ove:1tual y lea.d to death of the host. This 
'ltiE.S a factor 1vhic~ led Greens nan ( 26) to susces t th~.t t'-le 
failure of :achol and \'.rolc'-1 ( 1 2) to de;:;:1onstr,9 te ccr:111eti ti ve 
inhibition of AmiY'opterin uith FA co ld have been the result 
of this enzyrw des true tior:. 
T'r:is co 1'Jeti ti ve in"iibi tion coDcept of tho ·nechanism 
of action of A:-1iropterin i'.'e.s further s trencthened by la tPr 
v10rk of Greens~;an , Goldln, and Vendetti (27), \iho "~-roucht 
attentior to the Dossi"bili ty of a secor:d enzyne , Enzyne '1 B" • 
.:.nis enzyr:1e vr;;; s theorized to convert CF to an unknown inter-
d . .L "X" me lave' ' from rhence the formate transfer to the purine 
rinf arises. '1.'1:-le one hour ti:01e interval v1hic:1. allo1,;ed pro -
tection by FA acai'1St k'1~ncoterir -v;as -oos tulo ted as the re -
- -
quirqd tir.1c for conversion o:: FA to C? vri th 11 resul tent com-
peti ti ve action of :JF fo:."' :=r:z:rne n.is is i n con~rast to 
t:.~e corcept l·r:--1-icr_ fornerly vras held th3. t this intervco.l rep-
resen-::..ed the tine necess2ry fo::.""' en 1""eti tion by Aninopterin 
for Enzy11o "A" only. 
terin acted slo';Tly and in an irreversible cal~ner on Snzyme 
11B11 i n a 'c..ypo of en ..:petitio~.., kno ':m as 11 in te:;.. ..... ference" ( 27) . 
- - ---·- ----
I 
I 
-
II I n summary , then , it ce.n be theorized that the FA 
Antagonists initially inhibit increasing quantities of Enzyme 
"A" ( 2 3 ) , and thus eff e ctively nrevent conv ersion " f FA to OF , 
and in continuing dosages a 11 binding 11 o f Erzy•ne " :S' ' occurs ~n 
an "interference" .aanner. ( 27) 
Diagrarnatically , the action of Amin opterin on FA 
me t abolis ill may be s hs\m as follovlS : ( 2? ) 
FA 
Aminouterin 
~-C IID""i 
OF en ~B~e ) X intermediate with subseauent 
formate incornorati on into 
Nucleic Acids. 
THERAPY ~'!I TH mH~ F8LI C AO ID .ANI'AGSNISTS 
In Farbe r ' s origi nal study (3) , the first antagonist 
administered vJas Pteroy1aspartic Acid , given in doses of 40 mg . 
a day for one month . The cJinical course of the patient was 
unaltered , howev8r , and the "l)atient went inexorably r; n to 
death, bu t post mortem examination revealed a hypo-
:plastic bone marrow v:i -'::.h fe\v i mmatu r e cells. 
Bet\veen 1947 and 1943 , studies were then ::Jade upon a 
se~ies of 16 c hi . dren with Amir opterin as the nrinciple anti -
f0 ic drue; . ( 3 ) Ten of these c ~i dren s'::o v·ed de.P ini te remis-
sions clinically ( disa~pearance of enlarge spleen, liver, and 
Jy:nph nodes) , and hema tologica ly , ( 1'TBCcount s howed a tendency 
to1vard normalcy , the -:)e rcen tag e of i mmatu re ce ls decreased , 
an ~he blast forms fell markedly in the neripheral blood ) . 
The bone marro\·T changes shov1ed either a decrease or dis -
II 
II 
apnearance of leukemic cells and in s0me instances, complete 
restoration of a normal pattern . The r emaining six of the 16 
total either died at the time of t he r e-oort or vrere definitely 
- / 
unimprovei . 
LiKe the introduction of the ni trogen mustards , the 
urethanes , ACTH and Cortisone for the treatment of acute 
leukemia , the new antifolicc were similarly received with high 
expectations and a renewed glimmer of ho-oe in the field of 
leukemic therapy . 
One of the earlier repo r ts closely follo wing Farber 's 
series was one of 14 cases (s ix children , two adolescents , 15 
and 17 , and six adults ) described by Sacks, Bradford , and 
Schoenbach (29 ) between April 1943 - June 1949 . These consis -
ted of four cases of acute myeloid leukemia , seven cases of 
acute lymphoid leukemia and three cases of acute monocyti c 
leukemia . Even in the firs t few widely scattered reports , 
it ~t.ras found that the efficacy of the antifolics ran a 
snectrum of effecLiveness agai nst these three tyoes of leuk-
emia. Sacks (29 ), and others (30 , 31 , 32 and 56) found that 
there was an ap1Jarent lack of r es ponse i n the acute monocytic 
type ( although this was contradicted in i•leyer ' s study (33) in 
adults )~ the best resuonse vras to be had with the acute 
lymphoid tyue , while the myeloid tyne ran an intermediat : 
course of susceptibility between the two . 
In their series, ~i ce et al (32 ) gave Aminopterin in 
daily doses of . 5 - 1.0 mg . to young children and found : 
complete r emissions for two r_,onths, consisting of a subjective 
========~=~~==========================================~==============9F====== 
(13) 
feeling of well being in the ua tient , objective imnrovement 
in the form of regression of lymphadenopathy and splenomegaly 
and loss of hemorrhagic tendacy , plus hematological improve-
ment in an improved erythrocyte count , return of the leuk-
ocytes to normal , increase in thrombocytes, and im~rovement 
of the bone marrow (10 percent or less immature leukocytes , 
~ --~ t\ 
number of megakaryo cytes , a nd norma~ L~E ratio ) in 15 
/ 
percen t of the patients , a partial r emission in 50 percent, 
while 35 uerc~nt obta:i.ned little benefit . 
Dame..,hek , ( 30 )/ at'"lother of the ear y w rkers n the 
use of antifo_lcs in acute eukemia/ used four antagonists in 
his study group of 32 patients : minopterin , A- methopterin , 
.Amino - an - f ol , and A- nino1;terin in daily doses of 1 - 4 mg ., 
2-5mg ., and 25 - 75 mg . , respectively , and using es sentially the 
same criteria for complete remission as defined by Farber (34)~ 
obtained it in 31 . 3 percent for at east two months. His 
results followed the pattern of effectiveness against the 
various types of leukemia as described by other investigators 
(29 , 31 , 32 ) since in 14 cases of lymnhocytic leukemia , six 
obtained remi ssions , in 11 granulocytic leukemias only three 
obtained remission , and in the four monocytic types, there 
were no r emi ssions , "'rha tsoever . 
In Wilson ' s large mixed series of 65 chil ren and 
adults with acute eukemia , (31) 11 excellent" cli nical and 
hematologicel remissions 1·.rere seen in 17 percent , partial 
remission in 29 percent , and no res uonse in 54 percent . 
( ~ 
I 
This observer has s·ccee nd in observing one of t he longes t 
remissions rec ~ rded --a 4 0 day r emi ssion in a patient in the 
1- 10 year old age group . 
~nis sa~e investigato r in another s eries (35) f ound 
t hat 39 percen t of those with initia thrombocytopenia res -
ponded to normal thr0rnbocytic evels , n r t merely a rise in 
t hrornbocy tes as required in the criteria for complet e remission. 
The thrombocyte level , in fact, was rega. rded by 
:-Iic _d e et al ( 36 ) as being of i mr.o rtant ur 0gn stic value in 
evaluation of treatmen t , in as much as, a decrease in thrombo-
cytes after FA antagonist treatmen t was often the first sign 
of approach exacerbation ; a~d in those treated w~o did not 
show a rise ~oward normal levels , i t couJ d be rega r ed as a 
fai 1 ure of co~p_ete re~i ssion , and any change t o the better 
v-.ould not ast any an'Jreciable time. 
Sc hoenba ch, Co lsk~ e nd Greens'Jan (37 ) in one of 
t hei r studies in 19 52 obtained five significant clinical and 
ob jec t ive remissions in eight acute e kem_a vie t ms with 
Arninonterin and A- methopterin , an 3u;rchenal et a l ( 3'-3 ) in a 
nuch larger and mo r e valid series f 97 children obtained a 
32 percent CGlfl nlete r emi s s i on fi gu re . 
Not as successful resu ts with t h e Antif'), ics v!ere 
renorted by Sav.ri tzky- et a l ( 39 ) who , usi ng A·ninoptE.rin and 
A-nino - an - f ol, fund :'ive -:)atier.ts out of 17 treate with 
Ami no ~ terin obtaining cl inica _ i m.,..,roverr.ent , but hematol ogic 
r e·1iss icm vras incrmnl ete , 'lr1hile in the 11 oatients treated 
1vi th Ami no - an - f ol , nly one case s hOi-red a transien t c inical 
( J 7) 
It has beAn s~o':'n, alPo , t rt e.ntifolic "'",herauy in 
acute le\'.:{e'nia of adults is fraucht ·~ri th failure ( 33, lt-C, 41,42). 
In fr-ur adt1l t DD tionts treQ te by ·ieyer ~nd ?;evll"'.!1 r ( 42) (two 
c ( ,_._ 
ly 1phogen,us, tv:o '"1Jelocenous leu1-Arnias), u<"'iPC kni~"o'Jterin \ 
in doses up to 5mg. uer day , there wns f ound no clinical or 
signif ican t heoatolo[ ic improvement in any of the patients , 
and ir a series of 25 a"iu l ts ·'i th acute l euker::ie. 7.-re~ ted 1rri th 
Amino-pterin by Gendel, Kraus , cr S.reen ( 40) only tHo remiss -
ions or a mere eight per ce~t were obt~inod, ore cr~nlete 
rer:~ission l as '.ed for six ;;,onths , and another lasted for four 
r1onths. 
!~any observers have ro~arkqd u on the defirite value 
of supDle·:.:~entary blood trensfusions md ar ti biotic therapy 
1d.th the anti folic drugs (3,29,30,36,43,57) and :Jameshek 
susgests there can be no doubt that the zealous, supportive 
l t i nl e bl ood transfusions .and antibiotic t~erapy has had a 
defirite effect in prolon:;inr: the survivel t i me of acute 
leukemia victims. Pevertheless, the results obt~ined with 
the FA inhibitors ~ve been real, the patient h~s h~1 objec-
t ive , ard )erhaps even more i'1l':>ortC1nt, e. subjcc"'"ive feeline- of 
\fell being . ( So11e of the c ~ild.ren actually vrere allovred t o 
r-:,o hom~ aJ:"li live rel". ti vely 'l:"'orwal i ves for "~er ods of tv-ro 
months ( 32 ) to 490 days ( 31) vri th c ompl ete re!Tlissions . ) 
Prolon::atior of life as 'luch as up to t TO yee.rs Pftar onset 
of treatr:wnt has been reported '-'ith FA ante-eonist :.herepy (32)~ 
l 
(13) 
The most optimistic reports (3 ,32 ,37, 53,59 , 60) have ~iven 
result~ in or ~er of a 50 perce~t res~onse to antifol ic therapy 
eithe in terms of a complete or partial remission . 
1DXICITY REACTIONS WITE T-E F0LIC ACID AKTAG0 ISTS 
Farber, in his first re~ort (3) on the temporary 
remissions obtained by the use of the antifo ics, described a 
nonsoecific s tomatitis with early ulceratiAn which he combated 
vlith c -·ude liver extract o::tnd FA. Unfortunately, toxic re-
act:on ( mild t o extre ~a severity) hasp agued every invest-
igator ~sing the antagonists , and t~ere have been no series 
re ported in the scope of this review in vhich some toxic 
'T!Enifestatlons have not aopeared . 
Sacks et al (29) reuorto bone marrow aulas a and 
alouecia urder prolonged therapy, and sug~ests tha t all of 
these phenomena were distinctly suggestive of FA deficiency , 
a view also shared by Mc~eil (44). The ulcerative areas 
,1 were described as '' scatte!'ed eryt~ema tou s areas on the V"'ngue 
an buccal mucosa ~overed by a dirty, gray - v-rhi te membrane. 11 ' 
Tne al onecia v..ras thnught to be analat;ous to s ~i: in disturbances 
seen in FA deficient animals . 
In Rice 's series ( 32 ) an interestin[! observation was 
described in that one-hal f of the na '".len ts 1t i th lymnhoc J·t ic 
leukemia died as a result nf G-I hemorrhage , the most lethal 
toxicit; of a , whereas none o~ the patients with myelocyt ic 
leukemia showed ulceration of the G-I tract . These obser-
vations v-Jere correlate '"i th the freauently n0ted clinical 
experiences (2~,31,32) of the greater susceptibilit •T of the 
ly~~hocytic ty~e to k1inonterin, in contrast to the myelo-
cytic type. 
According to Drmeshek (30), toxic reections usue ly 
a:r.rpear betvlGen 5-21 days efter the beginnin::, of treatl"ler't,and 
of the four ante.gcnists used in his e;roup, Aminonterir:,A-:ne-
thopterin, J .. mino-an-fol, an A-ninopterin; A:nino'Jterin proved 
particularly toxic in cor.rparinon to the other three . 
He acreed vrith Sachs (29) that the first oojective 
si ~n of toxicity to be noted ·~s s tomatitis, an ~ameshek 
added -c·::le subjective sy':lpto""~s of so:."e throat and mouth, anorexl 
and nauser, as ·sicns of anprot:.'.cu.lcg f u l l-blo;m toxic reactions. ll 
An inte:-es ... lnt; reac tioD re'Jorted by Dar'leshe:c ( 30) was 
the anpeo.r nee, after several m0nths of therepy, of a e-en -
eralizod bro1•Tr1 hyperpic1e:1te tion \vhich remained even after 
the antifolic treatmert \vas stooped. 1-Iis-':,ological studies, 
undertC~.'cer by \'laisT.an, :1ich:::on1, and Zimmer:nann (i+.:J) con -
fir:ned ':.heir earlier impression of the occurence of a true 
J.Jelar::Jr.:enosis, 1:mt ho-vr t'1.e antngcr:!ists affect the tyrosinase 
illocha;.!is,n has no:, yet been de-c,err.nned . 
? . ron"'ocytopenia and leukopenia. have been the most 
frequent heme.tolo~ic~l toxic re.s.ctions, and upon occe.sion, 
anemia · ~·i th aulasL? of the bone !Jlarro r has been renorted 
(29 ,31, 32 ,33 , 44) . 
The most le'.:..hal e feet of Am;nopterin hcs be"'n at-
tributed to S'Jontaneo .s herorrhage ( 'JO, 36), but !:ickle et 
(20 
11 
I 
a1 (36), c.lthoush agreeable ·,;ith the concept that lar,:;e dcses 
of Amino terin and 1 eukemia, itself, caused a t:: rombocyto-
uenia, a so ~elt thet i~filtrDtion and nressure of leukeQiC 
cells on vessel wa ls ca sed sone of the b eedinc, and in 
so~e instances, the presence of increased heparin-like sub-
st2nces in the blood stre~m miGht be im licated. They rec~rde 
the overall picture of fatal hemorrha.e:;e as being a combination 
of ~hese four factors, not merely a drug toxicity factor 
operating e.lone . 
Since the regression of toxic reecti ns to the drug 
usually begins with the n''"'Uth lesions of st ma. titis and sore-
ness, 3urc':enal ( 3g) ms suggested thp t these ee.:rly lesions be 
reger ed as a sisna.l of the anproach of :;'lore danger .us and 
lethal dis~urb~nces in the G-I tr2ct, and that 1hen these 
lesions do occur, tre,_tment should be continue v,ri ~h circl'lTI-
snec:.. 
Pathologically (75), the bone marrow shovred a dis-
appearar1ce cf megakaryocytes initially, follovied by a decrease 
in formation of the myeloid an re -cell series, and though 
the lymph id ele.:nents 'i"rere di "'1inishe in the marrow, :. ~ey 
persisted in the snleen and lymph n des, thoue-h activity was 
somewh..,t ecre.,sed. Just before u cere.tion in the colon, 
"secretion of "!lucous v.ras diminishe or absent and. Goblet cells 
'lrlere noted to be indistinct, a trophic or absent. 11 
Destruc:.ion of rorm 1 cells of the mucosal c-ands 
was rep aced by 11l ar e, imoattre, aty-pical e·')ithelial cells 11 • 
.u_ to sis ·fe.s e.c':,i ve, an1 occasiorlally t lis r~n~a.::-
( ') 
\ 
t ion apDear-=d ineffective and 11 u cerations with hemorr"'e.ge 
develo e ar~'""~und decenerati l'lg cystic glands . 11 
1'rtEAT.1:::; :2 OF TCXICI 'Y R':7:P.C J:'IOI:S 
Worlring bac'\r :ards fr"m t.1:1e orisi ne hyp . thesis that 
if FA caus9d the "acc9lerator nhenn>ne,nn 11 if'l 1eukem· c ce ls, 
FA if'lhi '.Ji t rs vrnnl r -~verse t':J.e ""'r~"'CGSS ; ear y ·rorkers ~·! th 
the antif:- ics reaso ed that -'l.ninistration of 3'A, tren, 
sh vl be ab e t reve~ e a~y tr""~xic ~~eno~e~a so reduced 
( 3,29 , 3C , ~5 • ~he r~ ults , howev er, ;ere nrt f~'""~~nd to offer 
I 
at"'y srca er l.mnr'"'VeTert in tnxici ty reac t_ ns t1:-.an '" r0 obtain-
ed by merely st pping the dru • 
~-1uch '"'f the 9ar1 y nioneer exner '!l en tal ~ ~rk c~'""~ncern -
ing this 1Jr'lblem vras one by Burche1.'1aJ ( lt.6 )1 v'ho found in 
vurk_rg uunn Ak4 strain cf mouse e kemia thet the Aminonterin 
eff ~ct unon the leukemia .l~ost could be b ocke~ c-mnletely 
by firs~ giving CF in dnses one- h2 f t one- thir the 
'"'ri inal amount of Anin ,..,terin ad.':nlnistered . Burc her; a , and 
Jacs b '"'n ( 47~ an0ther investicat'"' ~ fo·n thet CF was S~'""~~e 
1 2- 24 Ji~es ac active as PGA in nreverting the activity nf 
These fac:.s Cf""l ""-ed ,; ··h tr.e cnll "'!C-'-e ··ta f 
tr.e ir crKere vr'rn t ''eo r Z P. the f rst ''"'r>:.:able c nce""Jt of 
that CF , and not F . ··:P s t'"e rea l no tent ubs tan c e ca ~ab e of 
co'Ubating e~tifo 1 i c t rxicity . 
By clinic ·l trir _ , CF -ras sho·dn, iD eed, .. "'" be '"'Uch 
1l'"'re ef-"'"ct i ve thar !!'A in subse 1uent s-=ries of acute leukemia 
catients by v-"ri'"'us clinical rve"ti ra tors ( -:?:7 , 3°,Lt.'q , 49 ) i n 
( ')'")\ (" ( 
11 
reversins or re c n ant folic tox city reactions. 
l!.SIS~A'TO.,.., I'C' TREA1'.17 F , v:ITH THE F LIC ACID A:;TAGC IS rs 
~very case of acute e kemia treated with the FA 
antago ists, h ch has initia y responded,has eventua y, 
either in weeks or ~onths, become refractory to al further 
treatment. 
In studies conducted upon the Ak4 strain of leukemic 
mice ,~urchenal (50)} in 1950 developed a s b ine of le ~ emia 
• transp ant rhich he termed Ak4R, and 'l:lich sho ·Ted co'11 lete 
resistan~o to treatment ith Aminopterin.This ef nite c arac-
teristic csees ed by thi stra_n has rer.1ained thro t;h 10 
passaces in a1 imals vrh ch received no aminopterin, rha tsoever, 
in the transfer. Burc . enal offe::"ed or theoretical expla-
nations for the pheno~en~: 
11 ) .hbili ty of the res stant eu ernie cell to syn-
thesize its own PGA; 
2) t deaminate the antimetabolite at the 4 position 
o-:: pteridine; 
3) to methylate the 4-a::n n gr n• 
' 
4) An ncree. ed a ility of t~e host organism to de-
toxify the com und. fl 
Law and oyle (4Q) simi arly sho1::ed resistance in 
t~~ee separate sub ines f a transplantable lymphoid e -
kemia Ll210 in strain ba mice s ng A-~eth nterin,A-ninop-
terin,and A- eDopterin. I' ey found that after seven succes-
sive trans lants,resistance t~at deve ued to one of the an-
(~ ..,., 
ta,.,.onists ike 'lise s'b..oi:red resistance to the other t,.ro anti-
folies. In a ter investica tions (51) these sat:1e worl~ers found 
that in t 1:.'0 of the resistant s blines, the resistant leukerr ic 
cells were actually de..,erdant on the preseDce of the aD-::.a -
gonist for optimal sro·..,rtl-} . I'hey clai"':led that the transfor-
mation appeared to be a stable one in that the resistarce 
remained nespite transfer to animal hosts not given any 
FA antagonist at all. 
They { 43,5 .. <ened these changes to those occuring 
in bacteria grovm in the uresence of antibiotics v..rhere :nany 
1orkers have concluded that the resistance origiDates through 
r 
I 
I 
I 
I 
I 
genetic changes,and the drug acts in a selective ~anner 0nly, I 
thus re~ovins the suscentible me~bers of a Dopulation and 
alloving the resistant for~s to reproduce. 
In a still later study Law (52) continuing his ure-
) 
vi~us brilliant expori~ents presented evidence disputing Pur-
chena ' s early Dostulates of dea~ination and nettylation of 
the anta.sonis+,,or of synthesis of PGA de novo,as r1ethods of 
the leuxe~ic eel acquiring resistance.Ee found that reither 
PGA or CF provided for ontimal growth of the resistant cells, 
and,in addition, CF actually partially blocked the use of FA 
antae:;ol"'ist by resistant cells.Furthermore,Lav/ disar reed 'lith 
3urchenal ' s fourth suggestion of increased host ability to 
detoxify PGl antaeonist, in that in his stud es, toxic re-
actions from the antifolics ¥ere not seen in mice growing the 
resistant leu!-e~Jic cell:: beca se the antinetabo i -::.e 1,;as ac-
---------- --- - - ----
( ?' 
tuall y being used in s 'J':lorting 0ptimal growth, a.s eviderced 
by the dif:erential ir growth capacities of resistant cells 
given the antifolic an those acking it . Detoxification 
thorefore, could be an explanation for the resistance, but 
not for the depen~ence cha!'ac t eristic. 
La1-r ' s iDvestication see~ed to postulate t he ability ,I 
of the transformed leul{emic cel l to use A- rJethopterin vli thout 
any corcversion to PGA or CF, thereby using ar entirely dif -
ferent route for nucleic e.cid synthesis than ,:l"lich is nor mal-
y used. Later, 'Surchenal, Johnston , and ,,<Taring (53) using 
similar experinental nrocedures asreed that an excellent 
possibi ity existed of an c:.lternate metabolic pathway by-
passing the CF e.s a probable mechanism of antif0lic resis -
tance . 
Some investicators (51) have offered the tlmely sug-
gestion that if mutation and selecticn are co11cJusively pro - ' ,, 
ven to be the origin of resistance to the differe·nt anti -
leukemic asents ( v1hich seems hishly nrobable at the present 
time ), antifolic therapy vlill n..ave to be adjusted to n eet 
thi s new concept of its effec t on e9erging resistant cells. 
Therapy Hould then have to be given as early as pas-
sible "at '"naxi'Ilun tolerate osa~es an continued as long as 
feasible sing anti-leul>: e"ic acents that are t :novm to be 
ir:dependent of each other ir their actions." In such a way, 
only leu1<::e'1ic cells Y ~ h i'iere resistant to "Yl ixtures of anti-
le l::e;nic a p·ents ( i . e . , those having numerous metabolic path-
----- ---=-~-
( '1)) 
re~ain as resistant ce s,an e~~re~ely rare cir-
cu,.,stance . 
~EC:;~rT DEVJ:LOP :Ei 'TS ' ' w IIC ACID A:i TAGO:riSI' J';ISP.APY 
.:any investicators,usir.~ the method of approach as 
outlined by Lavr and 3oy e (51~ have no~~~ begun to use the plar 
of alternatinG anti - e·~e ~ic a~ents in combating acute eu-
lre~ia and have s cceeded in definitely prolonging the life 
of soJe of t~eir uatients (55). 
In an nteresting series done by Pil,ers et al (54) 
t ro crou'Js f Da tients vrerfl 1.1.sed. ()t"'e sroup recei V8 AC TH ard. 
Cortisone 'nti no further imurove·1ent ,,.,ras noted,and then 
t he·· ';•J"ej_"e S1'Ti tched to Aminopterin therapy. .:.'he other croup 
received Am_nopterin ·until ae;a_ ro f rther _r;rprove::1ent v:as 
seen, after ~:hie "A t;:,is oerios 1.-:as chan ed to ACTE and Cor-
tis ore. rr:hey fourd t'1a t in a'ldi tion to prolonginG the re-
~ission period by this plPn, even f, rther remissions cou d 
be obtained in 50 per cent of the r patients by reverting 
to t he f rst ty. e f t era~y;after refractoriness had been 
developed in the second . 
Dr . .i.!..liel of the 01~lahoma .Iedical c:tesearch Insti tutB 
(55) s ~cested as a ?Ossi~le there y regimen: init al treat-
~ ent vri t ' the re,·Jly deve O'Jed 1J r ne antaronis ts, 6- 'T!erce.u-
to~urine~ ( uhic'-1 yield f<ister reT!littsions than thP FA in-
h .- . t ) d ~· , . ~..... , !Ol 1 o_ ors c>.n liC.en, ;,.,r ,~en resJ.s v ~!lee nc:.s eveloped to these, 
therapy can then be E r1 tched to an ."1tifo c; after t his , .. ]TH 
a Cortisone, and t her- or"!:laps, back acain to an a r1 tas nist 
of _P]z.rine or ?A. -----=~ -- ---~ 
:::'he ef:'icac i"' sYl.ess of "Si'1..:::; t'1o anti -l e ,,..o~ic a c:;er..ts 
ii1 coi'1bination,ro,t'1er t av one at a time, ::..s currently being 
investigated (55). Je, el and G::."'eenberg ( 69) save pre i minary 
renorts of t:1is nethod,experic:n_e:YJtally, in J.nr 1,1953, 1-rhen 
t~ey co~bined A-~ethopterin ard one of the 2,4-~ianinonyri ­
midines 01-50- 197), ;l:lic~ c:,re considered to have a mec 1anism 
of action similar to the FA a· tar;onists (70-7 ! . They found 
that a 92 ner cent increase in survival ti~e occured in mice 
·ri th Ll210 leult:enia in dosa;es, '·;'lUch, 1fr en c;i ven a one, :.-rere 
entirel! ineffective. 
Regarding ~ew 1et~o s of counteractinc tho toxicity 
factors, l·o in ot al ( 6?) using eocentia y the sa.'1e type of 
OX"1eri ---:.or.ts as Sc:..,oenbaclJ. ( 25 ( lllc'l cone erned the te·"'"1oral 
~elati~ns _i~s of Aminontor_n,CF, and FA adu~ ~ist~ati on) re -
ported in April , 1~53, t~1.u. t tho antioetaboli te - ::1ete.boli to 
ratio on the noop astic ce did not "entire y paralle the 
ef ·"ect on the host" . These \vorl{ers sugc;ested, in vieH of this 
observation, t11a t an initial f\_gh ose of Aoil1opterin i:JOu d 
selocti vely :la:::1a :e the neoulas tic cells, a d t 1;.a t a s bse-
quent delayed -lassive dose of CF could t en offer ryrotection 
to the host ·.Jefnre any 5re-: t amo nt of toxicity occure . 
..f SU.; :A:qy 
1. :''' e -o ssi"ole roles o:' FA :netabolisr:I as -:JOstulatod 
by several exper.:'TieLto:-s seems to revolve aro nd the 1-
tir.1ate conversion of FA to OF ·ri t.1 a la i o Forcate r-roup-
inr :'he subseo_uent for~:ate tra~sfer and incorryo:ration int 
......, • 
~ - r- I' D (27) 
,. 
I 
the purine structure is an essential step in nucleoprotein 
synthesis . 
2 . The the retical a ction of Aminopterin has been r~ 
d 7 d ' ·,..., -~ ... ~ '; !") 
arded by a number of investi cators to interr'l..rot- FA metabo -
- I' 
lism in the conversion of FA to CF by '1 competitive inhibition'' 
1--11 th enzyr:1e e.nd. to interrupt CF to an 11 X11 IJ:"lterrJ.ediatG 
y '' interference 11 \vi th enzyme "B" . 
3. Remissions , complete and partial , have bGen ob-
served in approxi~ately 50 per cent of all child patients 
vrho :1ave been under the the antifolic therapy revievmd in 
thi s pa er. 
4. Complete rerni ssior(" (i.e . ~linical and hematolo-
Gical) have been observed in fro~ approxi2atel y 15 to 30 ner 
cent of patients in reports l"'ev ievmd in this paper and have 
lasted fror-~ t •.-o l:lor,c.lls to a record 490 days inono isolated 
inswance. 
5 . 0 the t hre e mt: jor types of acute lou.;:e:mia, the 
t2.gonists, the ::1yelo senous t;rre TI9J:t '1ost suscenti'b e, D.nd 
the ::'OJ."lf".'C -":,ic t.ype , :..:le lor s"c suscep ui _..le of eJ.l to GherC.})Y . 
6 . Adult v.cute 1Gu1te!1i a 'b..as been seen to be com lote-
y re~·ractor·y to ant::.folic there.py . 
7. ,..oxic r.::actio~ s have Ecco,...,:xwie all antifolic 
res ponses and have r an ged from mild stomatitis and alopecia 
to severe gas t ro - intes t i nal hemorrhagE' uith. subs e quent 
d e&.th of the patient . 
The toxicity reactions have been most succ ess -
fully combated vith CF , ·rhic h '.1as superceded the use of FA 
and crude li vor extre.ct as a ::."eVOT'So.l a c ent. 
9 . All s"L.ccess::.'ul re:Jissions of acute leu'recia r:.ve 
beco:Je :."efr" c tory to !:.he an tlfnlics sooner or l n. ter, and t ~o 
"os t pr'O~)." ble cause o"!: this :-esis '-:.one e is a muta tiona cl12.nc;e 
e.n.d. nE~turo. sel , ctiol" Drocess :hic~1 c:J lo"t·:s thuso leul'"G.-"ti c cells, 
1 
i·rhich havo devo oped al te:i.."rl.? te .:--etabolic "lJD. th1· o.ys in tho for:w.-
1 
tion of nucleic acids, to su rvive. 
10. 'Ti th t 'li res is tanco ccnce·f)t in T'lir.d , it has bee-n · 
xlvise the/.:, c.cu to leukemia nou be trea. ted vri th a barrq;;e of 
asents utilizinG the antifo ics, ACIH and Cortisone, aDd the 
ne'.-; !?.:1ti . rino , 5 - 'Jo:.""capto:"Jurine . These should be used 
separately until resistance develo"Js , t:1en one c:f' tre re -
!!lB..inin':) ar--ents 1,-ri th a different r.:.ode of actior. shm.1ld be used. 
Co··1blned usage of one aseDt :ri t _ ano"c.her is still under i nves -
tisation , t houch one c;roun of .rorkers hc>s renort od "Jerked 
s cc ess '·;i th thiP :Jethod unon ex:_Jeri:nental ani ··;als. 
C"'" CLUSIC-
As in l""' Os t C 3 S ·3s ir ·rhich a n v; dru::; is under trial 
usac e, results V"Y'Y tre~endo sly a.~o~s investigators; 2n 
cx:.re·;os i"' r esnor:cive no8s to FA antac:nists have varied 
~ro"'1 excellent re,issiors (31, 32, 37, 51, 59, oO ) to ex-
tre1 ly essir1istic reuorts (33, 40, 41, 42 , 61, 62) . 
An ex.,..,lc.nr "',ior. of 'c..'1.e Hide varie"':Ji li :,y of response 
in mc.n~r of the c oses ,.,ps o-''':'ored "Jy Far':ler (62) v!ho stated, 
(?9) 
~ 
II 
, "no t"o cti '.reo 1·;i th acute le lw~1a presept strict y OOI'-
1 
jl 
il 
I 
p::>.ra. bl e pro bl o •ns " • Be a so cla.ined that the extent of bone 
ma.rrov invol ve:1ent ·"i th leuL:e"!lic ce ls has differed T>i th 
evo:.."'y case as have the factnrs res"'Jonsi b e f0r hle~din5, 
end the occurence of secondary infection. 
.Iany clinicians, a1'1nnr- them Dameshelr ( 63) in the 
United St~tes, and Colebatch and ~llia~s (64) of Australia, 
ques tior the use of -:.he ant i'olics at all, in viPvl of thnir 
manJ seve'"'0 toxic :ree.ctions. 
Dameshek ( 63) cn11siders -:.he diff~"'9nce be".:.>:een 
"irmrove 1en t,' ' and cn""'D ete re ··issiot"l a very :real one, sine e 
''i~.~prove'llent", as suc:1, ce.n be obtained in al~Jost all 
leuzemia >Jatients by SU")po:r-tive trrrsfusions R.nd artibiotic 
therapy ·vi thout usinr ary antifnlics. 
These critic isms are ce:rto, inly just fled, but vrere 
C~"'unte.i ... ed by Fe.rber ( 65) 1·rho offereQ. dofini te criteria for 
c0-"'Jl ete remission, and a stand.., rdiza tion 'Jrocedure of v-rai t-
ing t venty - one days e.:-:.er thore.py h,.,d beQ.Jr befoY>e pPtients 
co ld ~e cn~si .ered eli~ible for an antagonist rgs,orse. 
Usins thesP criteria , Forber nreserted data collected on 190 
patients over a four-ye." r period (one o~ the longos t s0:ries 
reJorted) and obtair.o4 co~~lete re·Jissio~s in '23.4% of <t 1 
t those s tudie~ B-nd co· nlete -~'eilure lr> on y 31. f5;t ( r.., -JlA 6). 
_oc~ (66 re~licd t o the toxi city ar~u~ont of 
De.J!1lishe}- (53) and others ( 64) by r>eference again to the 
~ 
}) series undertaker. at Chi l.~:r-en ' s Hos -oi tal, 3ostor, vrhe:re only I 
,1 
I 
I~ 
I 
il 
(f 
)) 
II 
r 
II 
~ 
II 
I 
/I 
any form of jl 
Gas tro-Intestt - , 
35"~ of all those v1ho ha.c'l C0""plete re "lission~ ha. 
toxicity . At tte time of his report, no seve~e 
!I 
I 
jl 
jl 
jl 
'I 
I 
Yle.l hemorrh:lf}'''S ·,rere e'1couutered in any of these re'"'cticns . 
11 
He attributed this success to t'1e be".:.ter vrderstan i!:"lt; and use 
of the antif0lics iP recent yer,rs . 
The treatr1ent o:~ e.cute leukoiT'ia is, at tne ~'"~"esent 
ti· e, shrouded if1 a vei of 11 .,...,8 e sn9ss and desnair . Vli th 
all the deve:o':lnents in the fie d -: its therapy, tre"~"e ie r:o 
lrno1m cure, and its otiolo~y is still questionable. 
The e.l"tifo ics an an tip J-ri.nes are !:J.ssu--nd to strilre 
nee.r ti1e very cenl:.er of Deoplastic ~rowth, i t.s v tal enzyme 
sys te~ . 'fueir e·Pficac7 has been ~ e ons tre ted in t·;.e r'UL1erous 
resissif"'ns res 1J':-ins from their use. A bold sten ':lcs been 
t<L:en, ar:d Fo ic Acid Antar-onis t I"h.erany of acute ouKemia 
see·:s to sl1.01·1 rl_efiDi te uror ise . 
Ree;e. rdine; the argument of a li 1i ted life prolon.<:"G.tion, 
evet1 idth ex ensive c ;,emothore.peut~c agents, ar obf'erva-'-iorJ 
of :.':le leu 1Ter- ic ;;ard of at1y child~ot1 1 s hosui ta 1 i 1 convince 
t'Qc most sl'3"'"ltical of the creat v2 e <f ;he e.r;t 'f"lics. 
T"no atti tu1e o tho "'lOre O'IJtinis-'-ic 1·or1-::ers in the 
field cc p be~' 1marize test, .erhcns , by t.e operinc wor s 
of" Shi lris 1.'\'"'.rreP at the Second O"nferonce 0!' FA A~ts.a-oniE" ts 
in '\'.h0 ~·rea tmen t of Leuk:e':li§. (57) : 
"All of s recor-ni 2 e th t t:J.8re is no real cure in 
si~ht 1;Jy t'.J.es~ ""Bans , "~ the other han , A. l of us reco?nize 
that a surprisi'1g 'iee;ree of arrest o the ne~"~~L::s'-ic rocess 
( '7., • 
r 
I 
I 
I 
has been obtain0d, both iD leu~~e::nia and in some o!' the 
solir tumors . 
I'he important thing is not th3.t any one particular 
compound achieves this end, but that vre have a mechanism, 
finally, by which, ·vii thout serious damage to '.:.he body as a 
\·:hole, or resoval of a oortion of the body, vre can ma terially 
affect tho Dew growth . 
The very fact that we have a number of cbemothera-
peutic agents --hormones, bacterial substances of various 
tynes, a wide veriety of FA a.ntagonists --makes it apparer:Jt 
that \<le are skirting close to the edge of some general rin -
cinle, e.nd that \>Tith further effort, it may not be houeless 
to fird r,-.rha t th<> t general princi -:)le is." 
j - '--=~--==~~~ ---- ---
1} (32) 
I' 
)) 
J 
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Group 
Dead Living :'otal 
~ 0 . % l o . .% No . % 
Complete remission 32 20 . 6 22 62.E 54 23 . 4 
Partial remission 3'5 23 . 2 6 17 . 2 42 22 .1 
Clini c~l tmurove-
·en -
17 10. 9 3 3. E 20 10 . 5 
Comulfte~r6~ission g 5. 2 1 2 . 9 9 4 . 7 
· l"".e .Lon; 
Partif±~~~ai~~~~n 5 3. 2 0 0 5 2 . 7 
Failure 57 36. 9 3 3. 6 60 31 . 6 
( Table 6 ) 
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